Navigation Links
Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Date:3/27/2008

NEW YORK, March 27 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that following a Drug Safety and Monitoring Committee (DSMC) review of the SUN-MACRO Phase 4 trial of Sulonex(TM) (sulodexide oral gelcap), the Company has decided to terminate the study and cease further development of Sulonex.

The Company previously announced via conference call on March 10th that the trial had been suspended pending an interim analysis, following which the Company would make a decision regarding whether the trial ought to be continued or terminated.

Based on a review of the available proteinuria data, Sulonex did not appear to be different than placebo. The study was not terminated by the DSMC for a safety problem or safety signal.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growt
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
2. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
5. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
6. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
7. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), a ... to treat obesity, metabolic diseases, and other gastrointestinal disorders, ... of its previously announced underwritten public offering of 40,229,886 ... per unit. Canaccord Genuity was acting ... acting as co-manager for the offering. The ...
(Date:7/6/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced today ... financial results on Monday, August 10, 2015, prior to ... will host a conference call and live webcast with ... August 10, 2015. The financial results and ... section of the Company,s Web site at http://investors.impaxlabs.com ...
(Date:7/6/2015)... 6, 2015  Nitin Tandon, M.D., UTHealth neurosurgeon ... Memorial Hermann Mischer Neuroscience Institute at the ... System technology into the skull of a 36-year-old ... seizures – the first time this procedure has ... "Epilepsy is a neurological condition that affects nearly ...
Breaking Medicine Technology:EnteroMedics Inc. Announces Termination of Public Offering of Common Stock and Warrants 2Impax to Report Second Quarter 2015 Results on August 10, 2015 2Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 2Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 3Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 4
... March 16 ExonHit Therapeutics,(Alternext: ALEHT) today reported ... by Institut Gustave Roussy, which describes the,identification of ... the,analysis of alternative RNA splicing [1]. Study data ... benign lesions, and alternative,transcripts determine the molecular characteristics ...
... WORTH, Texas, March 13 At the Health Industries ... Ph.D. and professor of public health and behavioral sciences ... Center,s School of Public Health, announced new findings ... economy. Specifically, unemployment and reduced spending on health ...
Cached Medicine Technology:ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform 2ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform 3ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform 4Unemployment, Health Care Spending Affect Mortality 2
(Date:7/7/2015)... , ... July 07, 2015 , ... Connexion Point is holding an onsite job fair ... held at 1769 Paragon Place, Suite 100, this upcoming Wednesday, July 8, and Thursday, July ... Connexion Point will be recruiting new applicants as well as holding onsite interviews. Interested ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... For ... finding medical providers for personal injury victims. Throughout the company’s history the goal ... deliver the care victims need in their recovery. And while Doctors on Liens ...
(Date:7/6/2015)... ... July 06, 2015 , ... PristineHydro ( ... all acids, chemicals and impurities; it also properly mineralizes the water with electrolyte ... harmful contaminants.  These harmful contaminants are a byproduct of how the water is ...
(Date:7/6/2015)... ... 2015 , ... On June 22, 2015, Fox News in a report titled “ Female Hair Loss Needs ... 35 a quarter of all women in the U.S. will suffer from thinning hair or ... rarely discussed. One woman, a former beauty queen, who was interviewed for the report began ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... year for aesthetic reasons, which is why liposuction regularly ranks among the top ... however, fat reduction has become more than a way to slim down a ...
Breaking Medicine News(10 mins):Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3
... of World Where Cancer is Easily Detected and ... ... 6-year,cancer survivor and president and CEO of Susan G. Komen for the ... Labor and Pensions on the need for comprehensive legislation to,address the nation,s ...
... 2008 Wouldnt it be nice if our doctors ... particular medication" This question is important because research ... to respond to treatments, but inevitably, differences among groups ... about groups of patients may not apply to individuals ...
... Hill-Rom Holdings,Inc., (NYSE: HRC ) invites you ... president and chief executive officer, Hill-Rom. He will ... York on Wednesday, May 21,at 8:30 a.m. EDT., ... live presentation via the internet,link at http://www.hill-rom.com ...
... eDiets.com, Inc.,(Nasdaq: DIET ), leveraging the power of ... to everyone, today announced that it will,report results for ... U.S.,equity markets close on Tuesday, May 13, 2008., ... investors the,following day, Wednesday, May 14, beginning at 8:30 ...
... Inc. (Phyhealth) (Pink Sheets: PHYH), a developer of ... that Phyhealth Plan Corporation, a wholly-owned subsidiary of,Phyhealth, ... Tampa, Florida to,provide dental services for its Pilot ... of 2008., Mr. Robert Trinka, chairman and ...
... May 8 Biopure Corporation,(Nasdaq: BPUR ) ... has received new funding of approximately $3.4 million ... being granted,through the Department of Defense for a ... of Polytrauma Combat Casualties,with Brain Injury and Concomitant ...
Cached Medicine News:Health News:Susan G. Komen for the Cure's(R) Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 2Health News:Susan G. Komen for the Cure's(R) Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 3Health News:Improving anxiety treatment through the help of brain imaging: A potential future treatment strategy 2Health News:eDiets.com(R) to Report First Quarter 2008 Results on Tuesday, May 13, 2008 2Health News:Phyhealth Signs Agreement with Argus Dental to Provide Dental Services for Pilot HMO 2Health News:U.S. Navy Receives Funding for Further Development of Hemopure(R) 2Health News:U.S. Navy Receives Funding for Further Development of Hemopure(R) 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: